Ambr 250 or Equal High Throughput Bioreactor System for NIAID VPP
ID: RFQ-NIAID-24-2220774Type: Combined Synopsis/Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

PSC

LABORATORY EQUIPMENT AND SUPPLIES (6640)
Timeline
    Description

    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking quotes for the procurement of two Ambr 250 or equivalent high-throughput bioreactor systems for its Vaccine Production Program (VPP). The primary objective is to replace aging equipment that has caused operational delays, thereby enhancing the efficiency of the Cell Culture Development team in their mission to develop vaccines for critical pathogens such as HIV and Ebola. This acquisition is vital for maintaining the VPP's operational readiness and ensuring timely progress in vaccine research and development. Interested vendors must submit their quotes by 3:00 PM EST on September 17, 2024, to Kathy Song at kathy.song@nih.gov, and must comply with all specified technical requirements and federal regulations outlined in the solicitation RFQ-NIAID-24-2220774.

    Point(s) of Contact
    Files
    Title
    Posted
    The file pertains to the Request for Quotation (RFQ) for the Ambr 250 or an equivalent high throughput bioreactor system for the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Processing Program (VPP), identified as RFQ-NIAID-24-2220774. The document presents a series of questions and answers relating to the solicitation dated September 16, 2024. Key points include the decision not to hold one-on-one calls with potential bidders to maintain the process's integrity, emphasizing that interested parties must adhere strictly to the outlined solicitation requirements. Additionally, it confirms the availability of standardized purchase order documentation for this category, specifically referencing the SF-1449 form under FAR Part 13, with a URL provided for access. Overall, the document serves to clarify procedural matters surrounding the RFQ, ensuring that all interested vendors understand how to submit their quotes properly and access required documentation without individual consultations. This is typical for federal procurements, emphasizing transparency and adherence to standardized processes.
    The document outlines a request for proposals (RFP) for an Ambr 250 or equivalent high-throughput bioreactor system intended for the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Program (VPP). It includes detailed specifications for system components, such as multiple packages for the Ambr 250, integration options with NovaFLEX2-ESM, Vi-CELL BLU systems, customizable modules, and various installation packages. Additionally, it lists delivery cost estimates and emphasizes the technical requirements needed for effective integration and operation. The project aims to advance biotechnological research by providing optimized high-throughput capabilities. The structured approach reflects the careful planning typical of federal grant projects and RFPs, ensuring adherence to regulatory standards and project specifications. Overall, it portrays a comprehensive planning effort to enhance research capabilities at NIAID.
    The document outlines contract terms and conditions required for compliance with statutes and executive orders relevant to federal acquisitions of commercial products and services, specifically focusing on federal grant applications and state/local RFPs. It lists various Federal Acquisition Regulation (FAR) clauses that contractors must adhere to, which cover areas such as prohibitions on contracting with certain entities, requirements for transparency in reporting executive compensation, and obligations regarding employment practices, including equal opportunity provisions. The clauses emphasized include those related to subcontracting, the use of small businesses, and labor standards. Additionally, it specifies the electronic submission of payment requests and mandates compliance with Section 508 accessibility standards for Information and Communication Technology. The intent is to ensure responsible contracting practices, promote small business utilization, and maintain the integrity of government functions in acquisitions. This reflects a broader commitment to regulatory compliance and ethical business practices in government contracting.
    Lifecycle
    Title
    Type
    Combined Synopsis/Solicitation
    Similar Opportunities
    Revio reagent kit, 24pack All reagents for sequenc
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure the Revio reagent kit, which includes a 24-pack of all reagents necessary for sequencing 24 Revio SMRT Cells. This solicitation aims to acquire essential laboratory supplies that are critical for advanced genomic sequencing applications. The Revio reagent kit plays a vital role in supporting research and development in the field of genomics and personalized medicine. Interested vendors can reach out to Dorothy L. Maxwell at dorothy.maxwell@nih.gov or call 301-827-7729 for further details regarding the procurement process.
    Reagent Generation for Bioanalytical Method Development on Biologics
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources for a potential contract focused on reagent generation for bioanalytical method development related to biologics. The primary objective is to obtain information on the availability and capability of companies to generate and deliver reagents, including anti-drug antibodies, that support the quantification of novel biologic drugs in various biological matrices. This initiative is crucial for advancing drug development processes and improving success rates in preclinical stages, with the Therapeutic Development Branch (TDB) at NIH playing a pivotal role in moving therapeutic candidates through the drug development pipeline. Interested parties must submit their capability statements by November 8, 2024, to Nick Niefeld at nick.niefeld@nih.gov, referencing sources sought notice number 75N95025R00007.
    BD Biosciences Proprietary Instrumentation Package and Reagent Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to procure a proprietary instrumentation package and reagent kits from Becton, Dickinson & Company for the Department of Laboratory Medicine. This acquisition aims to secure essential supplies, including instrument rentals and quality control materials, necessary for the operation of the Hematology Flow Cytometry Service, which plays a critical role in patient care and research. The procurement is vital for maintaining the laboratory's capacity to deliver timely and accurate results, as the specified reagent kits are uniquely compatible with the existing BD Rhapsody™ single cell analysis system. Interested parties may submit capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by November 14, 2024, at 6:30 AM EST, as this is a presolicitation notice and not a request for quotations.
    CYTEK AURORA 5 LASER WITH LOADER - UV/V/B/YG/R - PREMIUM SERVICE AGREEMENT
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for a premium service agreement for a Cytek Aurora 5 laser with loader, which is essential for advanced laboratory applications. The procurement includes comprehensive maintenance services, such as preventive inspections, technical support, and on-site assistance, ensuring optimal functionality of the equipment throughout the contract period from December 1, 2024, to November 20, 2025. This acquisition is critical for supporting the NIH's research initiatives in allergy and infectious diseases, emphasizing the importance of reliable laboratory equipment and services. Interested vendors must submit their quotations via the NIAID electronic Simplified Acquisition Submission System (eSASS) by November 13, 2024, at 12:00 am EST, and can contact Maliaka Pinkney or Jesse D Weidow for further inquiries.
    Qiagen LLC QIAsymphony DSP DNA Midi Kits, filter tips and supplies
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) intends to issue a sole source firm fixed-price purchase order to Qiagen LLC for QIAsymphony DSP DNA Midi Kits, filter tips, and related supplies, essential for the Microbiology Service section of the Department of Laboratory Medicine. This procurement aims to acquire reagents and supplies necessary for the efficient extraction of nucleic acids from clinical samples, which is critical for timely detection of infectious agents and supporting ongoing clinical testing. The items will be utilized with existing QIAsymphony SP and QIAgility instruments, which are vital for the laboratory's operations and the development of novel tests. Interested parties may submit their capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by November 14, 2024, at 2:30 PM EST, as this is not a request for proposals.
    Thermo Fisher Scientific Heracell Vios 160i CO2 Incubators Preventative Maintenance Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a firm-fixed price contract for preventative maintenance services for 54 Thermo Fisher Scientific Heracell Vios 160i CO2 incubators. This maintenance agreement is crucial for the Department of Transfusion Medicine, Center for Cellular Engineering Services, which manufactures cell-based therapies for clinical trials and is regulated by the FDA, necessitating that critical equipment is maintained in a controlled manner. The original equipment manufacturer, Thermo Fisher, is uniquely qualified to perform these services, including necessary software updates, to ensure compliance and avoid delays in patient treatments. Interested parties capable of providing similar services must submit a capability statement by November 16, 2024, at 12:00 PM EST to Sheri Eiri at sheri.eiri@nih.gov.
    NOI Cytiva Sepax C-Pro Cell Processing Systems Software Upgrade
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a firm fixed price contract for a software upgrade on two Cytiva Sepax C-Pro Cell Processing Systems. The objective of this procurement is to enhance the functionality of these systems, which are critical for the Department of Transfusion Medicine, thereby reducing the need for alternative devices and associated maintenance costs. This sole source acquisition is justified as Cytiva-Global Life Sciences Solutions USA LLC is the original equipment manufacturer and the only qualified provider for the proprietary software required for the upgrade. Interested parties must submit capability statements by November 14, 2024, at 12:00 PM EST to Sheri Eiri at sheri.eiri@nih.gov for consideration.
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Active
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.
    Vibrating Microtome
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources to provide a Vibrating Microtome for the National Institute on Aging (NIA). This acquisition aims to enhance research capabilities by enabling the preparation of autopsied brain tissue slices for microscopy analysis, which is crucial for studying neurodegenerative diseases such as Alzheimer’s. The specific model requested is the 7000SMZ-2, which features precision slicing capabilities and customizable operational parameters, with a delivery timeline of 12 months post-award. Interested parties must submit their capability statements by November 8, 2024, to Lorraine Gibbs at lorraine.gibbs@nih.gov or Angie Carpenter at angie.carpenter@nih.gov, ensuring compliance with federal acquisition regulations.
    A--National Gene Vector Biorepository (NGVB)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is preparing to issue a Request for Proposals (RFP) for the National Gene Vector Biorepository (NGVB) program, aimed at supporting translational gene therapy research over a five-year period. The selected contractor will be tasked with archiving over 20,000 clinical specimens under Good Laboratory Practices (GLP), developing assays for clinical testing, and maintaining a user-friendly web-based catalogue for gene therapy reagents, all while ensuring compliance with FDA regulations. This initiative underscores the government's commitment to advancing gene therapy research and enhancing the services provided by the NGVB. Interested parties should note that the RFP details are expected to be released on November 22, 2024, and can contact Ethan J. Mueller at ethan.mueller@nih.gov or +1 301 496 2153 for further information.